BioLexis Pte Ltd.

CIK 1716335 · Chief Executive Officer · last filed 2022-04-22

BioLexis Pte Ltd. is a Chief Executive Officer who has filed 10 SEC Form 4 insider transactions across 4 companies since 2017. The most recent filing, for OTLK, was dated Apr 22, 2022. Current disclosed insider exposure totals $1.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$1.52M

Companies

4

Total Filings

10

Lifetime Open-Market Net

$0

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
OTLK	10%+ Owner	1,149,126	$1.32	$1.52M	$0	1	2022-04-22
Outlook Therapeutics, Inc. (OTLKW) Delisted	Director	21,606,437	$0.03	$648.2K	$0	7	2020-01-29
Outlook Therapeutics, Inc. (ONSIW) Delisted	10%+ Owner	—	—	—	$0	1	2018-10-02
Outlook Therapeutics, Inc. (ONSIZ) Delisted	Chief Executive Officer	—	—	—	$0	1	2017-11-01

Recent Filings

10 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2022-04-22	OTLK	Other (J)	−27,982,529	$0	EDGAR
2020-01-29	Outlook Therapeutics, Inc. (OTLKW) Delisted	Mixed	+13,973,556	$3.24M	EDGAR
2019-07-01	Outlook Therapeutics, Inc. (OTLKW) Delisted	Other (J)	—	$0	EDGAR
2019-04-02	Outlook Therapeutics, Inc. (OTLKW) Delisted	Other (J)	—	$0	EDGAR
2019-01-03	Outlook Therapeutics, Inc. (OTLKW) Delisted	Grant (A)	+12,865,872	$12.00M	EDGAR
2018-12-31	Outlook Therapeutics, Inc. (OTLKW) Delisted	Other (J)	—	$0	EDGAR
2018-12-31	Outlook Therapeutics, Inc. (OTLKW) Delisted	Other (J)	—	$0	EDGAR
2018-12-06	Outlook Therapeutics, Inc. (OTLKW) Delisted	Grant (A)	+12,865,872	$12.00M	EDGAR
2018-10-02	Outlook Therapeutics, Inc. (ONSIW) Delisted	Other (J)	—	$0	EDGAR
2017-11-01	Outlook Therapeutics, Inc. (ONSIZ) Delisted	Buy (P)	—	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.